Status:
UNKNOWN
Development of a Response Signature to Neoadjuvant Chemotherapy for Breast Cancer
Lead Sponsor:
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Conditions:
Breast Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Breast cancer is the most frequent cancer in women. It is often treated with neoadjuvant chemotherapy, administered before surgical resection. Unfortunately, many patients do not respond to this treat...
Detailed Description
Breast cancer is the most frequent cancer in women. It is often treated with neoadjuvant chemotherapy, administered before surgical resection. Unfortunately, many patients do not respond to this treat...
Eligibility Criteria
Inclusion
- Women and men with breast cancer
- Treated with neoadjuvant chemotherapy
Exclusion
- None
Key Trial Info
Start Date :
August 7 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2019
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT03314870
Start Date
August 7 2017
End Date
December 31 2019
Last Update
July 15 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cliniques universitaires Saint-Luc
Brussels, Belgium, 1200